AbbVie
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
CEORobert A. Michael
CEORobert A. Michael
Employees55,000
Employees55,000
HeadquartersNorth Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded2011
Founded2011
Employees55,000
Employees55,000
ABBV Key Statistics
Market cap351.30B
Market cap351.30B
Price-Earnings ratio93.42
Price-Earnings ratio93.42
Dividend yield3.30%
Dividend yield3.30%
Average volume5.48M
Average volume5.48M
High today$199.83
High today$199.83
Low today$196.50
Low today$196.50
Open price$196.83
Open price$196.83
Volume4.68M
Volume4.68M
52 Week high$218.66
52 Week high$218.66
52 Week low$163.81
52 Week low$163.81
ABBV News
Seeking Alpha 14h
Genmab rises on late-stage trial win for AbbVie-partnered lymphoma therapyGenmab (GMAB) traded higher on Thursday after the Danish biotech, with its H1 2025 results, announced that its bispecific antibody epcoritamab, developed with A...
Analyst ratings
59%
of 29 ratingsBuy
58.6%
Hold
41.4%
Sell
0%
People also own
Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.